Abstract Objective To elucidate the background and clinical features of intrapulmonary hemorrhage in collagenvascular diseases (CVD) patients.
Introduction

Intrapulmonary hemorrhage, which is sometimes associated with collagen-vascular diseases (CVD), is potentially fatal (1-3). It includes both diffuse alveolar hemorrhage (DAH) typically in association with pulmonary vasculitides and hemorrhages other than DAH (non-DAH) that develop with thromboembolism or infections. We recently treated CVD patients with DAH that developed with thrombotic thrombocytopenic purpura (TTP) or with complicated Goodpasture syndrome. Although a decrease in the peripheral blood hemoglobin (Hb) level is typical during intrapulmonary hemorrhaging, its magnitude remains unclear. While peripheral blood total leukocyte (WBC) counts have been reported to increase, lymphocyte and platelet count changes have not been reported
.
In this study, we retrospectively examined our CVD patients with intrapulmonary hemorrhage, focusing mainly their underlying and associated conditions, changes in laboratory features, and therapies and outcomes. [8] wnl CMV esophagitis DAH nd: not determined, wnl: within normal limit, SLE: systemic lupus erythematosus, MPA: micropolyangiitis, SjS: Sjögren's syndrome, APS: anti-phospholipid syndrome, DIC: disseminated intravascular coagulation, TTP: thrombotic thrombocytic purpura, B-P: bronchial artery to pulmonary vein, A-P: internal thoracic artery to pulmonary vein, IP: interstitial pneumonia, CMV: cytomegalovirus, yr: year, m: month. 
T a b l e 1 . B a c k g r o u n d o f P a t i e n t s wi t h I n t r a p u l mo n a r y He mo r r h a g e
Patients and Methods
Of
DAH episodes
Fourteen DAH episodes developed in 9 patients. The major underlying diseases were SLE and MPA (Table 1) . (Fig. 2) F i g u r e 1 . P e r i p h e r a l b l o o d h e mo g l o b i n l e v e l a n d l y mp h o c y t e c o u n t b e f o r e a n d a t o n s e t o f i n t r a p u l mo n a r y h e mo r r h a g e . DAH me a n s d i f f u s e a l v e o l a r h e mo r r h a g e . B a r s s h o w me a n ± S . D. 
DAH was diagnosed on autopsy in Patient 3 (SLE), on transbronchial lung biopsy in Patient 4 (SLE), 7 (MPA), 8 (MPA) and 10 (MPA), by bronchoalveolar lavage in Patient 5 (SLE), 9 (MPA) and 11 (MPA/SLE), and by clinical findings including hemoptysis and infiltrates in Patient 6 (SLE). The second DAH episode of Patient 11 (MPA/SLE) was noted by chance on tracheal tube insertion for a bone fracture operation. Eight patients other than Patient 11 had a fever. XP/CT revealed mottled ground-glass opacities (GGOs) distributed diffusely in the lungs
F i g u r e 2 . a : Ch e s t CT o f P a t i e n t 4 a t h e mo r r h a g e o n s e t . b : P l a i n c h e s t X-P ( b -1 ) o f P a t i e n t 8 t a k e n t wo mo n t h s b e f o r e t h e CT s c a n ( b -2 ) .
ADAMTS13 activity was only slightly decreased (26% in Patient 5 and 48% in Patient 9).
Laboratory findings in DAH patients
Regarding the data analysis, the blood cell counts prior to the onset of hemorrhage in Patient 8 (MPA), who had repeated blood transfusions, were excluded. In DAH patients, the Hb level decreased from 9.3±2.2 (n=13) to 6.8±1.5 g/dL (n=14, p<0.0001) at 0.5±0.7 g/dL/day (Fig. 1) (Fig. 1) .
The 
Discussion
In this study, MPA patients who developed DAH showed a substantially higher MPO-ANCA level than the normal upper limit (9.0 U/mL), and SLE patients who had it showed a high SLEDAI score, as defined as 'severe' or 'active' in the literature (13, 14 T a b l e 2 . Du r a t i o n f r o m S y mp t o m On s e t t o Di a g n o s i s o f I n t r a p u l mo n a r y He mo r r h a g e , T r e a t me n t s a n d Ou t c o me syndrome, hardly being differentiated from each other, was reported occasionally (15, 16) . Goodpasture syndrome or positive GBM has been reported in several CVD cases (17) (18) (19) (20) (1, 3, (21) (22) (23) (24) (25) . Recently, in contrast to that deficient ADAMTS13 activity causes idiopathic or hereditary TTP, endothelial involvement has been shown to contribute to TTP pathogenesis in CVD patients (26, 27 
